Plaintiff brings this action pursuant to 8 Del. C. § 220 (“Section 220”) to enforce Plaintiff’s statutory right to inspect certain books and records of Defendant.
Public information about CV and its directors’ materially false and misleading statements – including, for instance, a call with investors where the Company stated it “continues to execute” its plan to secure FDA approval for CVSI-007 even though the USPTO had twice rejected its patent application – supplies a credible basis to suspect wrongdoing that warrants investigation, but that information is insufficient for Plaintiff’s purpose of investigating that wrongdoing and for his separate but related purpose of investigating the independence of each of the Company’s directors and officers.
A copy of the complaint can be viewed here:
To learn more about this action, contact us today!